These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Reversal of glucose-induced hyperkalemia by sodium restriction in normaldosteronemic diabetes: evidence for elevated mineralocorticoid threshold. Rado JP Biomedicine; 1981 Sep; 35(4):109-11. PubMed ID: 7295860 [TBL] [Abstract][Full Text] [Related]
3. Reversal of glucose-induced hyperkalemia by sodium restriction in "normaldosteronemic" diabetes mellitus. Radó JP Endokrinologie; 1981 Dec; 78(2-3):244-52. PubMed ID: 7037374 [TBL] [Abstract][Full Text] [Related]
4. A possible role for human growth hormone (HGH) in the protection from glucose-induced hyperkalemia in normaldosteronemic diabetes. Radó JP Endokrinologie; 1982 Nov; 80(3):364-6. PubMed ID: 7166165 [TBL] [Abstract][Full Text] [Related]
5. Regulation of plasma aldosterone by glucose-induced paradoxical hyperkalemia in the presence of suppressed renin-angiotensin system. Radó JP Endokrinologie; 1978 Apr; 72(1):51-6. PubMed ID: 688983 [TBL] [Abstract][Full Text] [Related]
6. Glucose-induced paradoxical hyperkalemia in patients with suppression of the renin-aldosterone system: prevention by sodium depletion. Radó JP J Endocrinol Invest; 1979; 2(4):401-6. PubMed ID: 395185 [TBL] [Abstract][Full Text] [Related]
7. Interplay of various factors in glucose-induced hyperkalemia during captopril treatment. Radó JP; Gercsák G; Bános C Int J Clin Pharmacol Ther Toxicol; 1986 Feb; 24(2):69-76. PubMed ID: 3514489 [TBL] [Abstract][Full Text] [Related]
8. Effect of mineralocorticoids on the paradoxical glucose-induced hyperkalemia in nondiabetic patients with selective hypoaldosteronism. Rado JP Res Commun Chem Pathol Pharmacol; 1977 Oct; 18(2):365-8. PubMed ID: 918352 [TBL] [Abstract][Full Text] [Related]
10. Big renin and biosynthetic defect of aldosterone in diabetes mellitus. deLeiva A; Christlieb AR; Melby JC; Graham CA; Day RP; Luetscher JA; Zager PG N Engl J Med; 1976 Sep; 295(12):639-43. PubMed ID: 184384 [TBL] [Abstract][Full Text] [Related]
11. Prediction of hyperkalemia associated with prolonged treatment with captopril by glucose-induced acute serum potassium changes. Radó JP Exp Clin Endocrinol; 1984 Oct; 84(2):143-7. PubMed ID: 6396097 [TBL] [Abstract][Full Text] [Related]
12. Early onset of hyperkalemia in patients treated with low molecular weight heparin: a prospective study. Koren-Michowitz M; Avni B; Michowitz Y; Moravski G; Efrati S; Golik A Pharmacoepidemiol Drug Saf; 2004 May; 13(5):299-302. PubMed ID: 15133781 [TBL] [Abstract][Full Text] [Related]
13. Glucose-induced hyperkalemia developing in the upright position in captopril-treated hypertensives. Radó JP; Bános C; Gercsák G; Molnár Z; Pató E; Csabuda M Res Commun Chem Pathol Pharmacol; 1982 Oct; 38(1):161-4. PubMed ID: 6755590 [TBL] [Abstract][Full Text] [Related]
14. Successful treatment of hyperkalemic quadriplegia associated with spironolactone. Radó JP Int J Clin Pharmacol Ther Toxicol; 1988 Jul; 26(7):339-45. PubMed ID: 3061940 [TBL] [Abstract][Full Text] [Related]
15. "Outpatient hyperkalemia" syndrome in renal and hypertensive patients with suppressed aldosterone production. Rado JP; Boer P; Dorhout Mees EJ; Simatupang T J Med; 1979; 10(3):145-57. PubMed ID: 289714 [TBL] [Abstract][Full Text] [Related]
16. The renin-angiotensin-aldosterone system in diabetic patients with hyperkalemia. Sunderlin FS; Anderson GH; Streeten DH; Blumenthal SA Diabetes; 1981 Apr; 30(4):335-40. PubMed ID: 7009278 [TBL] [Abstract][Full Text] [Related]